Immunosuppressive therapy of cyclosporin A for severe benzene-induced haematopoietic disorders and a 6-month follow-up

Chemico-Biological Interactions

Volumn 186, Issue 1, 2010, Pages 96-102

  Song, Yuguo ^a,b   Du, Xuqin ^a,b   Hao, Fentong ^a,b   Gu, Xiaoxin ^c   Zhang, Zhenghua ^d   Zhang, Songquan ^e   Li, Chunsheng ^a,b   Li, Huiling ^a,b   Ma, Jing ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Beijing National Centre for Clinical Toxicology   (China)

^c Jinan Municipal Nationality Hospital   (China)

^d Department of Occupational Medicine   (China)

^e Department of Occupational Medicine   (China)

Author keywords

Benzene; Cyclosporin A; Follow up; Severe haematopoietic disorders

Indexed keywords

ANTIBIOTIC AGENT; BENZENE; CYCLOSPORIN A; HEMOPOIETIC GROWTH FACTOR; IMMUNOGLOBULIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TESTOSTERONE UNDECANOATE;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; MALE; OUTCOME ASSESSMENT; PNEUMONIA; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BENZENE; BONE MARROW DISEASES; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC TESTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYELODYSPLASTIC SYNDROMES; OCCUPATIONAL EXPOSURE; TESTOSTERONE; YOUNG ADULT;

EID: 77952950842     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.03.049     Document Type: Article

References (38)

1. Wang L., Zhou Y., Liang Y., Wong O., Armstrong T., Schnatter A.R., Wu Q., Fang J., Ye X., Fu H., Irons R.D. Benzene exposure in the shoemaking industry in China, a literature survey, 1978-2004. Regul. Toxicol. Pharm. 2006, 46:149-156.
2. Huan P. Advances in adhesives used in the shoe industry. Guangdong Chem. Eng. 2000, 1:13-16.
3. Zheng Y., He F. Human Health Information of Chemical Exposure in China 2009, Accessed at http://www.nihs.go.jp/GINC/meeting/8th/8profile/yuxin.pdf, on May 15, 2009.
4. Zhao C.X., Luo R., Li J.G., Zhu H.B., Zhao W. Analysis on the benzene poisoning event about Gaobeidian's bag industry in 2002. Chin. Occup. Med. 2003, 30:32-34.
5. Brandão M.M., Rêgo M.A., Pugliese J., Clarencio J., Bastos C.M., Ferreira J., Meyer R., Neves M., Freire S.M. Phenotype analysis of lymphocytes of workers with chronic benzene poisoning. Immunol. Lett. 2005, 101:65-70.
6. Irons R.D., Gross S.A., Le A., Wang X.Q., Chen Y., Ryder J., Schnatter A.R. Integrating WHO 2001-2008 criteria for the diagnosis of Myelodysplastic Syndrome (MDS): a case-case analysis of benzene exposure. Chem. Biol. Interact. 2009, 10.1016/j.cbi.2009.11.016.
7. Velasco L.R., Barrera E.E., Munoz T.A., Tapia A.R., Gonzalez R.C., Garci{dotless}a L.M., Ortiz M.V., Betancourt R.M. A model for the induction of aplastic anemia by subcutaneous administration of benzene in mice. Toxicology 2001, 162:179-191.
8. Toxicological Review of Benzene, Non-cancer Effects 2009, Accessed at http://www.epa.gov/iris/toxreviews/0276-tr.pdf, on January 20, 2009.
9. Hayes R.B., Yin S., Rothman N., Dosemeci M., Li G., Travis L.T., Smith M.T., Linet M.S. Benzene and lymphohematopoietic malignancies in China. J. Toxicol. Environ. Health A 2000, 61:419-432.
10. Brodsky R.A., Sensenbrenner L.L., Jones R.J. Complete remission in acquired severe aplastic anemia following high-dose cyclophosphamide. Blood 1996, 87:491-494.
11. Brodsky R.A., Jones R.J. Aplastic anaemia. Lancet 2005, 365:1647-1656.
12. Chen J., Liu W., Wang X., Chen H., Wu J., Yang Y., Wu L., Yang D. Ex vivo immunotherapy for patients with benzene-induced aplastic anemia. J. Hematother. Stem Cell Res. 2003, 12:505-514.
13. Li Y.Q., Han S.F., Yang L.J., Chen S.H., Zhou Y.B., Chen J.Y., Liu W.W. Significant decrease of recent thymic output function in patients with severe benzene intoxication. J. Exp. Hematol. 2005, 13:114-117.
14. Irons R.D., Lv L., Gross S.A., Ye X., Bao L., Wang X.Q., Ryder J., Armstrong T.W., Zhou Y., Miao L., Le A.T., Kerzic P.J., Ni W., Fu H. Chronic exposure to benzene results in a unique form of dysplasia. Leuk. Res. 2005, 29:1371-1380.
15. Wang H., Bi Y., Wang C., Tao N., Xia Y., Zhang L. cDNA microarray and cluster analysis to identify the significance of immune genes associated with benzene poisoning. Chin. J. Ind. Hyg. Occup. Dis. 2005, 23:260-262.
16. Diagnostic Criteria of Occupational Benzene Poisoning (GBZ68-2002) 2009, Accessed at http://www.gdpcc.com/standard/standard68.htm, on April 20, 2009.
17. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
18. Camitta B.M., Doney K. Immunosuppressive therapy for aplastic anemia: indications, agents, mechanisms, and results. Am. J. Pediatr. Hematol. Oncol. 1990, 12:114-122.
19. Unal S., Cetin M., Tavil B., Calişkan N., Yetgin S., Uçkan D. Favorable outcome with allogeneic hematopoietic stem cell transplantation in pediatric acquired aplastic anemia patients. Pediatr. Transplant. 2007, 11:788-791.
20. Buthbumrunga N., Mahidol C., Navasumrit P., Promvijit J., Hunsonti P., Autrup H., Ruchirawat M. Oxidative DNA damage and influence of genetic polymorphisms among urban and rural schoolchildren exposed to benzene. Chem. Biol. Interact. 2008, 172:185-194.
21. Renz J.F., Kalf G.F. Role for interleukin-1 (IL-1) in benzene-induced hematotoxicity: inhibition of conversion of pre-IL-1 alpha to mature cytokine in murine macrophages by hydroquinone and prevention of benzene-induced hematotoxicity in mice by IL-1 alpha. Blood 1991, 78:938-944.
22. Niculescu R., Bradford H.N., Colman R.W., Kalf G.F. Inhibition of the conversion of pre-interleukins-1 alpha and 1 beta to mature cytokines by p-benzoquinone: a metabolite of benzene. Chem. Biol. Interact. 1995, 98:211-222.
23. Kalf G.F., Renz J.F., Niculescu R. p-Benzoquinone, a reactive metabolite of benzene, prevents the processing of pre-interleukins-1 alpha and -1 beta to active cytokines by inhibition of the processing enzymes, calpain, and interleukin-1 beta converting enzyme. Environ. Health Perspect. 1996, 104(Suppl. 6):1251-1256.
24. Whysner J., Reddy M.V., Ross P.M., Mohan M., Lax E.A. Genotoxicity of benzene and its metabolites. Mutat. Res. 2004, 566:99-130.
25. Li Q., Geiselhart L., Mittler J.N., Mudzinski S.P., Lawrence D.A., Freed B.M. Inhibition of human T lymphoblast proliferation by hydroquinone. Toxicol. Appl. Pharm. 1996, 139:317-323.
26. Lv L., Kerzic P., Lin G., Schnatter A.R., Bao L., Yang Y., Zou H., Fu H., Ye X., Gross S.A., Armstrong T.W., Irons R.D. The TNF-alpha 238A polymorphism is associated with susceptibility to persistent bone marrow dysplasia following chronic exposure to benzene. Leuk. Res. 2007, 31:1479-1485.
27. Kerzic P.J., Pyatt D.W., Zheng J.H., Gross S.A., Le A., Irons R.D. Inhibition of NF-kappaB by hydroquinone sensitizes human bone marrow progenitor cells to TNF-alpha-induced apoptosis. Toxicology 2003, 187:127-137.
28. Hirano K., Ichikawa T., Nakao K., Matsumoto A., Miyaaki H., Shibata H., Eguchi S., Takatsuki M., Ikeda M., Yamasaki H., Kato N., Kanematsu T., Ishii N., Eguchi K. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl. 2008, 14:292-298.
29. Ferraccioli G.F., Tomietto P., De Santis M. Rationale for T cell inhibition by cyclosporin A in major autoimmune diseases. Ann. N.Y. Acad. Sci. 2005, 1051:658-665.
30. Poggi A., Zocchi M.R. Cyclosporin A regulates human NK cell apoptosis induced by soluble HLA-I or by target cells. Autoimmun. Rev. 2005, 4:532-536.
31. Scheinberg P., Wu C.O., Nunez O., Scheinberg P., Boss C., Sloand E.M., Young N.S. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 2009, 94:348-354.
32. Rosenfeld S., Follmann D., Nunez O., Young N.S. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003, 289:1130-1135.
33. Teramura M., Kimura A., Iwase S., Yonemura Y., Nakao S., Urabe A., Omine M., Mizoguchi H. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 2007, 110:1756-1761.
34. Yoon B.I., Hirabayashi Y., Kawasaki Y., Kodama Y., Kaneko T., Kim D.Y., Inoue T. Mechanism of action of benzene toxicity: cell cycle suppression in hemopoietic progenitor cells (CFU-GM). Exp. Hematol. 2001, 29:278-285.
35. Kuang S., Liang W. Clinical analysis of 43 cases of chronic benzene poisoning. Chem. Biol. Interact. 2005, 153-154:129-135.
36. Killick S.B., Mufti G., Cavenagh J.D., Mijovic A., Peacock J.L., Gordon-Smith E.C., Bowen D.T., Marsh J.C. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br. J. Haematol. 2003, 120:679-684.
37. Stadler M., Germing U., Kliche K.O., Josten K.M., Kuse R., Hofmann W.K., Schrezenmeier H., Novotny J., Anders O., Eimermacher H., Verbeek W., Kreipe H.H., Heimpel H., Aul C., Ganser A. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004, 18:460-465.
38. Chen S.C., Jiang B., Da W.M., Gong M., Guan M. Curative effects of cyclosporin A therapy upon myelodysplastic syndrome. Natl. Med. J. China 2006, 86:2711-2715.